Evaluation of antibody targeted controlled release nanoparticle systems
抗体靶向控释纳米颗粒系统的评估
基本信息
- 批准号:G1001805/1
- 负责人:
- 金额:$ 5.79万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2011
- 资助国家:英国
- 起止时间:2011 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The overarching objective of this proposal is the pilot evaluation of a novel antibody-drugdelivery technology, developed by the academic partner (Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46), using novel therapeutic antibodies that have beendeveloped by the industrial partner. Pursuance of this objective will provide the following:1. Development of the Research Fellow?s research expertise, management and leadership2. Development of new patent applications around the data produced3. Technical and commercial evaluation of a new therapeutic approach by the partners4. Development of a portfolio of data to facilitate future project grant application funding toagencies such as the MRCThis project builds on the established links between the industrial and academic partners.These groups have successfully collaborated in the past, producing joint IP, publications inquality journals (Clinical Cancer Research, Bioconjugate Chemistry and PlosONE), andultimately creating jobs and wealth in the local economy. A previous collaboration, focussedon the transfer of a protein engineering technology from the School of Pharmacy (through aKTP scheme; awarded A in final report; regional winner 2008), led to the development of anew bovine TB diagnostic kit by the company, which is currently undergoing evaluation in theUK and Ireland.In this current project, the academic partner has developed a novel nanoparticulate drugdelivery system and has already been provided with commercially insensitive antibodies totest as a proof of principle in vitro by the industrial partner. This project will build on thisbase, examining commercially prioritised antibodies (produced using the platformtechnologies underpinning the company) in relevant in vivo primary and metastatic tumourmodelsWe believe that this programme is an ideal mechanism to fund this pilot project, as it not onlyprovides the scope to undertake the project, but allows the Fellow to learn and champion thetechnology, thus developing their own CV, and provides a framework for further fundingopportunities from the MRC such as the DPFS
该提案的总体目标是对学术合作伙伴开发的新型抗体药物递送技术进行试点评估(Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46),使用工业合作伙伴开发的新型治疗性抗体。追求这一目标将提供以下内容:1。研究员的发展?的研究专长,管理和领导2。围绕所产生的数据开发新的专利申请3.合作伙伴对新治疗方法进行技术和商业评估4。开发一系列数据,以促进未来向MRC等机构申请项目资助该项目建立在工业和学术合作伙伴之间的既定联系之上。这些团体过去曾成功合作,制作联合知识产权,在高质量期刊(临床癌症研究,生物缀合物化学和PlosONE)上发表论文,并最终为当地经济创造就业机会和财富。以前的合作,侧重于从药学院转移蛋白质工程技术,(通过aKTP计划;在最终报告中获得A; 2008年区域赢家),导致该公司开发了新的牛结核病诊断试剂盒,目前正在英国和爱尔兰进行评估。在目前的项目中,学术合作伙伴开发了一种新的纳米颗粒药物输送系统,并已提供了商业上不敏感的抗体,以作为工业合作伙伴的体外原理证明。这个项目将建立在这个基础上,(使用支撑公司的平台技术生产)在相关的体内原发性和转移性肿瘤模型中我们相信,该计划是资助该试点项目的理想机制,因为它不仅提供了开展项目的范围,而且允许研究员学习和支持技术,从而发展自己的简历,并为MRC(如DPFS)的进一步资助机会提供了框架
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Scott其他文献
Prevalence and Prognostic Implications of Pulmonary Hypertension in Patients With Severe Aortic Regurgitation
严重主动脉瓣反流患者肺动脉高压的患病率及其预后意义
- DOI:
10.1016/j.jacadv.2024.100827 - 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Vidhu Anand;Christopher Scott;Alexander T. Lee;V. Rigolin;Garvan C. Kane;H. Michelena;S. Pislaru;Gabor Bagameri;Patricia A. Pellikka - 通讯作者:
Patricia A. Pellikka
An investigation of the impact of speaking the Lumbee Dialect on the academic achievement and identity development of Native American college students
说伦比方言对美国原住民大学生学业成绩和身份发展影响的调查
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
Christopher Scott - 通讯作者:
Christopher Scott
Erratum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk (Nature Communications (2014) 5:5303 (DOI:10.1038/ncomms6303))
勘误:全基因组关联研究确定了与乳房 X 光密度和乳腺癌风险相关的多个位点(Nature Communications (2014) 5:5303 (DOI:10.1038/ncomms6303))
- DOI:
- 发表时间:
2015 - 期刊:
- 影响因子:0
- 作者:
S. Lindström;D. Thompson;A. Paterson;Jingmei Li;Gretchen L. Gierach;Christopher Scott;J. Stone;J. Douglas;I. dos;P. Fernández;Jajini Verghase;Paula L. Smith;Judith E. Brown;R. Luben;N. Wareham;R. Loos;J. Heit;V. Pankratz;A. Norman;E. Goode;J. Cunningham;M. deAndrade;R. Vierkant;K. Czene;P. Fasching;L. Baglietto;M. Southey;G. Giles;Kaanan P. Shah;H. Chan;M. Helvie;Andrew H. Beck;Nicholas W. Knoblauch;A. Hazra;D. Hunter;P. Kraft;M. Pollán;J. Figueroa;F. Couch;J. Hopper;P. Hall;D. Easton;N. Boyd;C. Vachon;R. Tamimi - 通讯作者:
R. Tamimi
Queer Rapture: Translating Ganymede from Ovid to Marlowe
酷儿狂喜:将木卫三从奥维德翻译成马洛
- DOI:
10.14418/wes01.1.659 - 发表时间:
2011 - 期刊:
- 影响因子:0.5
- 作者:
Christopher Scott - 通讯作者:
Christopher Scott
Comparisons of Resistance Training and “Cardio” Exercise Modalities as Countermeasures to Microgravity-Induced Physical Deconditioning: New Perspectives and Lessons Learned From Terrestrial Studies
抗阻训练和“有氧”运动方式作为微重力引起的身体不适对策的比较:地面研究的新视角和经验教训
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:4
- 作者:
J. Steele;P. Androulakis;C. Perrin;J. Fisher;P. Gentil;Christopher Scott;A. Rosenberger - 通讯作者:
A. Rosenberger
Christopher Scott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Scott', 18)}}的其他基金
Development of a Chemoproteomics Centre of Excellence: A Prosperity Partnership for Drug Discovery in Northern Ireland
化学蛋白质组学卓越中心的发展:北爱尔兰药物发现的繁荣伙伴关系
- 批准号:
BB/Y00325X/1 - 财政年份:2023
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
DRivers and Impacts of Ionospheric Variability with EISCAT-3D (DRIIVE)
EISCAT-3D (DRIIVE) 的驱动器和电离层变率的影响
- 批准号:
NE/W003384/1 - 财政年份:2022
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
Development of intracellular VNARs as novel tools to dissect intracellular biological processes
开发细胞内 VNAR 作为剖析细胞内生物过程的新工具
- 批准号:
BB/R009112/1 - 财政年份:2018
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
肿瘤启动序列与新型纳米颗粒药物载体相结合,增强胰腺癌的治疗效果:美国/北爱尔兰/爱尔兰共和国三方联盟
- 批准号:
MC_PC_15013 - 财政年份:2015
- 资助金额:
$ 5.79万 - 项目类别:
Intramural
Driving space weather forecasts with real data
用真实数据进行空间天气预报
- 批准号:
NE/J024678/1 - 财政年份:2012
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
Development of a novel anti-inflammatory nanoparticle for the treatment of Acute Lung Injury
开发用于治疗急性肺损伤的新型抗炎纳米颗粒
- 批准号:
MR/J014680/1 - 财政年份:2012
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
Pan-American Studies Institute (PASI): Adaptive Water-Energy Management in the Arid Americas; La Serena, Chile, 2013
泛美研究所(PASI):干旱美洲的适应性水能源管理;
- 批准号:
1242209 - 财政年份:2012
- 资助金额:
$ 5.79万 - 项目类别:
Standard Grant
Molecular and pharmacological validation of Cathepsin S as a novel target in cancer treatment
组织蛋白酶 S 作为癌症治疗新靶点的分子和药理学验证
- 批准号:
G0901615/1 - 财政年份:2010
- 资助金额:
$ 5.79万 - 项目类别:
Research Grant
CNH: Strengthening Resilience of Arid Region Riparian Corridors: Ecohydrology and Decision Making in the Sonora and San Pedro Watersheds
CNH:加强干旱地区河岸走廊的恢复力:索诺拉和圣佩德罗流域的生态水文学和决策
- 批准号:
1010495 - 财政年份:2010
- 资助金额:
$ 5.79万 - 项目类别:
Standard Grant
Workforce Training for Stem Cell Research
干细胞研究劳动力培训
- 批准号:
0920799 - 财政年份:2009
- 资助金额:
$ 5.79万 - 项目类别:
Standard Grant
相似国自然基金
CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
- 批准号:82371805
- 批准年份:2023
- 资助金额:45.00 万元
- 项目类别:面上项目
沙眼衣原体pORF5蛋白功能及其与宿主细胞相互作用的研究
- 批准号:30970165
- 批准年份:2009
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer
尿癌细胞培养 (UCCC) 尿液样本分析前因素的评估——一种非侵入性生物标志物 — 用于监测膀胱癌的反应和复发
- 批准号:
10640606 - 财政年份:2023
- 资助金额:
$ 5.79万 - 项目类别:
Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer
新型 ADAM10 调节剂治疗结直肠癌的临床前评估
- 批准号:
10697653 - 财政年份:2023
- 资助金额:
$ 5.79万 - 项目类别:
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
反映肝细胞癌β-连环蛋白激活的治疗预测因子的评估
- 批准号:
10437906 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
新型TNFR2拮抗单克隆抗体用于CTCL治疗的临床前毒理学和药理学评价
- 批准号:
10772580 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
反映肝细胞癌β-连环蛋白激活的治疗预测因子的评估
- 批准号:
10277385 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Lead Optimization and Evaluation of Anti-SN38 Payload Binding Selectivity Enhancers
抗 SN38 有效负载结合选择性增强剂的先导优化和评估
- 批准号:
10325518 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
新型TNFR2拮抗单克隆抗体用于CTCL治疗的临床前毒理学和药理学评价
- 批准号:
10323802 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
反映肝细胞癌β-连环蛋白激活的治疗预测因子的评估
- 批准号:
10693135 - 财政年份:2021
- 资助金额:
$ 5.79万 - 项目类别:
Culturally-targeted communication to promote SARS-CoV-2 antibody testing in saliva: Enabling evaluation of inflammatory pathways in COVID-19 racial disparities
以文化为目标的沟通促进唾液中 SARS-CoV-2 抗体检测:能够评估 COVID-19 种族差异中的炎症途径
- 批准号:
10221254 - 财政年份:2020
- 资助金额:
$ 5.79万 - 项目类别:
Culturally-targeted communication to promote SARS-CoV-2 antibody testing in saliva: Enabling evaluation of inflammatory pathways in COVID-19 racial disparities
以文化为目标的沟通促进唾液中 SARS-CoV-2 抗体检测:能够评估 COVID-19 种族差异中的炎症途径
- 批准号:
10855010 - 财政年份:2020
- 资助金额:
$ 5.79万 - 项目类别: